| Controls N=12 | RA N=16 | SLE N=13 | P value |
Female sex, n (%) | 8 (67) | 10 (63) | 13 (100) | 0.05 |
Age, years | 49 ± 15 | 51 ± 13 | 43 ± 9 | 0.18 |
Hypertension, n (%) | 0 | 3 (19) | 2 (16) | - |
Diabetes, n (%) | 0 | 0 | 1 (8) | - |
Hyperlipidaemia, n (%) | 0 | 3 (19) | 0 | - |
BMI, kg/m2 | 24 ± 3 | 25 ± 3 | 27 ± 5 | 0.12 |
Chloroquine, n (%) | N/A | 11 (69) | 11 (85) | - |
Methotrexate, n (%) | N/A | 15 (94) | 1 (8) | - |
Prednisolone, n (%) | N/A | 2 (13) | 9 (69) | - |
Leflunomide, n (%) | N/A | 3 (19) | 1 (8) | - |
Sulfasalazine, n (%) | N/A | 3 (19) | 0 | - |
Azathioprine, n (%) | N/A | 0 | 4 (31) | - |
Rituximab, n (%) | N/A | 2 (13) | 1 (8) | - |
DAS28-CRP | N/A | 5 ± 1 | N/A | - |
SLEDAI (median, IQR) | N/A | N/A | 7 (4-11) | - |
ESR, mm/hr (median, IQR) | N/A | 7 (5-10) | 10 (4-16) | - |
CRP, mg/L (median, IQR) | 1 (1-1) | 5 (2-7) | 4 (2-6) | <0.001 |
Duration of disease, years (median, IQR) | N/A | 11 (7-14) | 13 (6-16) | - |
Duration of DMARDs, years (median, IQR) | N/A | 7 (5-11) | 8 (3-11) | - |